Glen Brooks, MD
Plastic and Reconstructive Surgery · Longmeadow, MANPI 1588637847
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $72,189 of the $77,677 with a category attached, or 92.9%. AbbVie accounts for 95.6% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2021 at $59,043 and has fallen 97.8% since, to $1,281 in 2025. Among plastic and reconstructive surgery clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 197 payments — averaging $394.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$74K
- Sientra, Inc.$2K
- Revance Therapeutics, Inc.$689
- Solta Medical, A Division Of Bausch Health US, LLC$111
- TELA Bio, Inc.$78
- Urogen Pharma, Inc.$58
- plus $64 from 2 others
What the payments were for
- Consulting fees$1,5002%
- Speaking & faculty fees$72,18993%
- Food & beverage$3,9885%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 155 | $74,291 |
| Sientra, Inc. | 13 | $2,386 |
| Revance Therapeutics, Inc. | 22 | $689 |
| Solta Medical, A Division Of Bausch Health US, LLC | 2 | $111 |
| TELA Bio, Inc. | 1 | $78 |
| Urogen Pharma, Inc. | 1 | $58 |
| Calyxo, Inc. | 2 | $46 |
| Pacira Pharmaceuticals Incorporated | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$77,677 in reported general payments places this provider in the 95th percentile of 67 plastic and reconstructive surgery providers in Massachusetts.
See all plastic and reconstructive surgery providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other plastic and reconstructive surgery in Longmeadow
- Kyle EberlinBoston$445K
- Guy RochmanMilton$125K
- Dennis OrgillBoston$87K
- Jonathan FriedstatBoston$59K
- Ashley BoustanyBoston$46K
- Devin O'Brien-CoonBoston$34K
- Raymond DunnWorcester$31K
- Jonathan BekiszBoston$23K
- Krystle TuanoBoston$20K
- Christopher HomsyBoston$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.